Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest

Rana, Obaida R.; Schröder, Jörg; Baukloh, Julia K.; Saygılı, Esra; Mischke, Karl; Schiefer, Johannes; Weis, Joachim; Marx, Nikolaus; Rassaf, Tienush; Kelm, Malte; Shin, Dong‐In; Meyer, Christian; Saygili, Erol

doi:10.1016/j.ijcard.2012.12.016

Cited by 51 publications

(39 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Like serum NfH SMI35 , serum NfL Umea47:3 may also be exploited as a safety biomarker for recognising neurotoxicity [21]. There is already data that serum NfL levels are of comparable prognostic value to NfH SMI35 levels following cardiac arrest [19,23]. Of note there were no controls and no analytical validation data from the NfL assay used in one study [23].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

et al. 2013

View full text Add to dashboard Cite

ObjectiveNeuronal damage is the morphological substrate of persisting neurological disability. Neurofilaments (Nf) are cytoskeletal proteins of neurons and their release into cerebrospinal fluid has shown encouraging results as a biomarker for neurodegeneration. This study aimed to validate the quantification of the Nf light chain (NfL) in blood samples, as a biofluid source easily accessible for longitudinal studies.MethodsWe developed and applied a highly sensitive electrochemiluminescence (ECL) based immunoassay for quantification of NfL in blood and CSF.ResultsPatients with Alzheimer’s disease (AD) (30.8 pg/ml, n=20), Guillain-Barré-syndrome (GBS) (79.4 pg/ml, n=19) or amyotrophic lateral sclerosis (ALS) (95.4 pg/ml, n=46) had higher serum NfL values than a control group of neurological patients without evidence of structural CNS damage (control patients, CP) (4.4 pg/ml, n=68, p<0.0001 for each comparison, p=0.002 for AD patients) and healthy controls (HC) (3.3 pg/ml, n=67, p<0.0001). Similar differences were seen in corresponding CSF samples. CSF and serum levels correlated in AD (r=0.48, p=0.033), GBS (r=0.79, p<0.0001) and ALS (r=0.70, p<0.0001), but not in CP (r=0.11, p=0.3739). The sensitivity and specificity of serum NfL for separating ALS from healthy controls was 91.3% and 91.0%.ConclusionsWe developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum (NfLUmea47:3); levels in ALS were more than 20-fold higher than in controls. Our data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Several reports have suggested peripheral blood levels of NfH as a potential marker of neurodegeneration [13–22]. In contrast to this, there is only one recent study investigating serum NfL; this paper examined the relationship between serum NfL and neurological outcome following cardiac arrest [23]. …”

Section: Introductionmentioning

confidence: 99%

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

et al. 2013

View full text Add to dashboard Cite

show abstract

“…14 Of the candidate blood biomarkers, most data are available for neuron-specific enolase (NSE) and S-100B, but other biomarkers have also been investigated. 11,13,[15][16][17][18][19] NSE is a dimeric enzyme, mainly expressed in neurons, and its half-life is estimated to 24-30 h. 13 Red blood cells contain NSE, and therefore, hemolysis affects NSE levels. 11,13 Increased NSE concentrations after CA are associated with poor outcome in comatose patients, but there is as yet no established cut-off value for this marker.…”

Section: Introductionmentioning

confidence: 99%

Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome

et al. 2014

View full text Add to dashboard Cite

“…Additionally, in our study there were no significant differences in serum NEFL levels between measurement before and after CEA. To find a specific neuronal marker of a long‐term neurological outcome, Rana et al examined serum levels of NEFL in patients after cardiac arrest. Their study suggested that within 7 days after cardiac arrest, serum NEFL is a valuable marker of long‐term neurological outcome.…”

Section: Discussionmentioning

confidence: 99%

Effect of carotid endarterectomy on brain damage markers

et al. 2016

View full text Add to dashboard Cite

Data from our study showed that CEA affects serum YKL-40 but not NEFL and FABP7 levels. This implicates that YKL-40 may be a valuable serum marker of brain damage after CEA. However, the observed change in serum YKL-40 level in patients after CEA does not necessarily warrant a change in recommendations concerning the use of this treatment in patients with high-grade internal carotid artery stenosis.

show abstract

Neurofilament light chain as an early and sensitive predictor of long-term neurological outcome in patients after cardiac arrest

Cited by 51 publications

References 30 publications

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome

Effect of carotid endarterectomy on brain damage markers

Contact Info

Product

Resources

About